17. June 2025
ERC Advanced Grant “Reloaded”!
We are thrilled to announce that Frank Buchholz has been awarded the highly competitive European Research Council (ERC) Advanced Grant. His project titled “DNA-binding domain Conditioned Precision…
5. May 2025
New research project on CRISPR technologies in national funding initiative
Our research group has received funding of 117,000 EUR for our research project titled "Pioneering molecular surgery with CRISPR technologies for personalized lung cancer therapy." As part of the…
5. February 2025
Medical Revolution from Saxony: CAR-T Cell Therapies in Focus
Take a look at this news article about SaxoCell, a research cluster funded by the BMBF, in which our lab is actively involved! Link to news article Link to SaxoCell website
29. January 2025
Milica Jelicic honoured with Carl-Gustav-Carus-Förderpreis 2024
On January 28, 2025, the Carl-Gustav-Carus-Förderpreis 2024 was awarded at the Faculty of Medicine of TU Dresden in recognition of outstanding scientific achievements. One of the awardees is Milica…
3. December 2024
We are co-organising the DG-GT 2025 Annual Meeting!
We are excited to host the upcoming DG-GT Annual Meeting in Dresden, focusing on the theme "From lab to life – Genome editing towards therapies." We are organizing the meeting together with Deutsche…
25. October 2024
Liliya Mukhametzyanova receives Dr Walter Seipp Prize
Liliya Mukhametzyanova was awarded the Commerzbank Foundation's Dr Walter Seipp Prize for her dissertation on ‘Increasing the utility of evolved site-specific recombinases for genome editing’. With…
30. August 2024
SaxoCell enters second phase of funding!
We are excited to share that SaxoCell has been chosen by the Federal Ministry of Education and Research (BMBF) and an independent expert panel to receive funding for a second phase in the…
30. April 2024
Lukas Theo Schmitt honoured for his PhD thesis
On 27 April 2024, the DRESDEN EXCELENCE AWARD was presented to four graduates of Dresden universities by Lord Mayor Dirk Hilbert who honoured their outstanding scientific theses. Among the awardees…
24. April 2024
Prof. Dr. Frank Buchholz receives Reinhart Koselleck grant!
We are delighted to announce a Reinhart Koselleck project in our research group! The German Research Foundation (DFG) has awarded Frank Buchholz a 1.25-million-euro research project on the topic…
8. March 2024
Contributing with talk and posters to DG-GT’s 30th Annual Meeting in Munich
Frank Buchholz and members of his research group attended the 30th Annual Meeting of the German Society for Gene Therapy (DG-GT), titled Nucleic Acid Therapeutics: Genetic Indications and Beyond held…
31. January 2024
New Nature paper from our lab on groundbreaking genome editing tools unlocking new possibilities for precision medicine
Our new Nature Biotechnology paper "Activation of recombinases at specific DNA loci by zinc-finger domain insertions” has just been published! It describes a newly developed method combining the…
18. January 2024
Wirtschaftswoche “Start-up of the week”
Newspaper "Wirtschaftswoche" votes Seamless Therapeutics as "Start-up of the week". In this newspaper feature, start-ups pitch their business idea. This time it's Seamless Therapeutics and expert…
7. November 2023
New publication from our lab
Check out our brand-new publication on "Quantification of evolved DNA-editing enzymes at scale with DEQSeq". Congratulations to everyone involved!
6. September 2023
Frank Buchholz honoured for his commitment to transfer innovation from research to industry
On 6 September 2023, UNIPRENEURS honoured 20 outstanding professors & founders for their achievements in transfer of innovation who had been selected from 700 nominations. Prof. Dr. Frank…
1. September 2023
Frank Buchholz and Seamless Therapeutics GmbH on designer recombinases competing with CRISPR
In our latest news release, Frank Buchholz (TU Dresden) and Anne-Kristin Heninger (Seamless Therapeutics GmbH) look at how designer recombinases have become a strong competitor of CRISPR. Explaining…
30. June 2023
Laborjournal on Seamless Therapeutics
In their news article in Laborjournal, the Dresden-based start-up Seamless Therapeutics reflects on programmable recombinases that operate independently of the cell's own DNA repair system and could…
22. May 2023
Jenna Hoersten represented the Buchholz Lab at the 26th ASGCT Annual Meeting in Los Angeles
The American Society of Gene and Cell Therapy’s (ASGCT) Annual Meeting is considered the premier event for professionals in gene and cell therapy. Our PhD student Jenna participated at this year's…
9. May 2023
New publication on tyrosine-type site-specific recombinases
Our new paper “Discovery and characterization of novel Cre-type tyrosine site-specific recombinases for advanced genome engineering” in collaboration with DKMS Life Science Lab has just been…
21. April 2023
Frank Buchholz participating in open discussion on genetic research
Is there a gene for a bigger and more efficient brain? Can genome surgery soon free us from all diseases? Do my genes determine my character? During audience discussions, experts exchange views on…
16. March 2023
The TU Dresden Spin-off Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases in Dresden
Seed round co-led by Wellington Partners and Forbion, with additional non-dilutive financial support from the BMBF (GO-Bio funding) enables maturation of the proprietary platform and pipeline…
16. March 2023
Frank Buchholz featured in DHMD podcast “You Ask We Explain”
A new episode of the podcast series “You Ask We Explain” by Deutsches Hygiene-Museum Dresden (DHMD) features Prof. Dr. Frank Buchholz. Titled “It’s all a question of genes. The chance of limitless…
13. March 2023
Dresden Excellence Award for Dr. Felix Lansing
Dr Felix Lansing has won the Science Award of the City of Dresden in the doctoral category and was honoured for his dissertation work “Wie neuartige Gen-Skalpelle die Gen-Therapie revolutionieren –…
22. February 2023
Shady Sayed wins Young Investigator Award
Our postdoc Shady Sayed is one of the winners of the Young Investigator Award of the 21st International AEK Cancer Congress. The Young Investigator Award in the amount of 500 EUR was awarded by the…
19. February 2023
Shady Sayed representing the Buchholz Lab at the 21st International AEK Cancer Congress in Kassel
Shady Sayed’s abstract has been selected as an abstract short talk at the 21st International AEK Cancer Congress in Kassel from February 15 to 17, 2023. The abstract titled “Efficient Correction of…
16. December 2022
Deutscher Studienpreis award ceremony for Felix Lansing in Berlin
For this groundbreaking contribution to finding treatment for more then 8,000 diseases that can be traced back to gene defect, Felix Lansing was awarded second place in the Deutscher Studienpreis of…
22. August 2022
Felix Lansing awarded Deutscher Studienpreis in Natural and Technical Sciences
Dr Felix Lansing has made a groundbreaking contribution to cell and gene therapy, for which he was awarded 2nd place in the Deutscher Studienpreis by the Körber Foundation. “In my dissertation,”…
25. May 2022
New start-up company RecTech GmbH founded
RecTech GmbH is a brand new start-up focused on developing designer recombinases for precision genome editing. Supported by the BMBF GO-Bio programme, the lab of Frank Buchholz founded the company to…
21. January 2022
Designer recombinase can precisely correct disease-relevant gene defect in severe form of hemophilia A
The research team led by Prof. Frank Buchholz at the Carl Gustav Carus Medical Faculty of the Technical University of Dresden has succeeded in developing an enzyme that can efficiently and…
21. January 2022
Interview on communication in science with Prof. Dr. Frank Buchholz
On 18 January 2022, mdr Sachsen published a podcast on the topic “Is there a therapy for Long Covid?” in which Prof. Dr. Frank Buchholz comments on communication in science within and with the…
20. December 2021
Prof. Frank Buchholz new Dean of Research at the Medical Faculty
As Dean of Research, Prof. Frank Buchholz will continue the previous work and set new priorities. The objective of the Office of the Dean of Research at the Medical Faculty of the TU Dresden is: - to…
8. December 2021
German Alliance of Scientific Organisations: Call for more objectivity in crisis situations
The German Alliance of Scientific Organisations has taken a stand on the current reporting by the BILD newspaper in connection with the coronavirus pandemic by calling for more objectivity in crisis…
2. December 2021
BMBF Cluster4Future SaxoCell® focusses on therapeutic options for previously incurable diseases
At the kick-off meeting on 16 November, the BMBF Future Cluster was launched with the vision of establishing an independent industry in Saxony that will focus on “living medicines”. Prof. Frank…
21. July 2021
Frank Buchholz among this year’s Falling Walls finalists
Frank Buchholz has been selected as a finalist for the Falling Walls Science Breakthroughs of the Year 2021 in Life Sciences. The award recognizes ground-breaking work contributing towards solving…
12. July 2021
Business Plan Competition – RecTech team from Dresden wins second place at Science4Life Venture Cup
The Dresden research team has developed a promising business concept to revolutionize molecular medicine based on a customized designer recombinase technology. This genome editing technology is…
14. May 2021
Science4Life – The Dresden RecTech team has successfully participated in the competition again
The Dresden start-up project RecTech led by Prof. Frank Buchholz and Dr. Anne-Kristin Heninger emerged as one of the winners at the Science4Life TechSLAM on May 11, 2021. Within this competition, 20…
11. March 2021
The tailored genome – How enzymes can help to cure hereditary diseases
The start-up project RecTech led by Prof. Frank Buchholz and Dr. Anne-Kristin Heninger has once again succeeded in scoring points in the prestigious Science4Life Venture Cup. This time, RecTech was…
30. November 2020
Start-up RecTech is one of the winners of the 2021 Science4Life Venture Cup first phase
Within the business plan competition of the 2021 Science4Life Venture Cup, 97 applicants presented their innovative business ideas and 5 teams were awarded with a prize for the best business idea.…
6. November 2020
Development of a powerful gene editing tool to correct a genomic inversion frequently found in Hemophilia A
Hemophilia A (HA) is the most commonly occurring inheritable deficiency of blood coagulation. Severely affected individuals suffer frequent spontaneous haemorrhaging, which can lead to chronic…